Sobi publishes Q4 2024 report: A solid ending to a strong year

Swedish Orphan Biovitrum AB Sweden

or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.

To participate in the conference call, please use the following dial-in details:

Sweden: [phone]
United Kingdom: [phone]
United States: [phone]

For other countries, please find the details here.

Sobi

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 05 February 2025 at 8:00 CET.

Gerard Tobin
Head of Investor Relations

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-publishes-q4-2024-report--a-solid-ending-to-a-strong-year,c4100452

The following files are available for download:

https://mb.cision.com/Main/14266/4100452/3245896.pdf

Q4 and FY 2024 report. A solid ending to a strong year

 

View original content:https://www.prnewswire.co.uk/news-releases/sobi-publishes-q4-2024-report-a-solid-ending-to-a-strong-year-302368544.html